The Company is an early stage biopharmaceutical company dedicated to the commercial translation of the clinical knowledge and insights of Dr. Alan Shackelford, gained through his treatment of more than 25,000 patients using endocannabinoid therapies. The company is focusing on epilepsy in areas of high unmet medical needs.

Shackelford Pharma filed a provisional patent application related to the use of SP1707 for the treatment of acute and chronic seizure disorders, either alone or as adjunctive therapy. This application included both supportive preclinical and clinical data.

At Shackelford Pharma, Dr. Shackelford is supported by an expert medical and pharmaceutical team with a wealth of experience in clinical research and development, drug development, commercial operations, and marketing, to manage the development and commercialization of pharmaceutical products.